BRIEF published on 06/27/2024 at 19:27, 4 months 23 days ago ABIONYX Pharma Achieves Unanimous Approval at Combined General Meeting Shareholders Biotech General Meeting Resolutions ABIONYX Pharma
PRESS RELEASE published on 06/27/2024 at 19:22, 4 months 23 days ago Informations privilégiées / Autres communiqués ABIONYX Pharma annonce l'approbation unanime des résolutions lors de son Assemblée Générale Mixte. Renouvellement des mandats et programmes approuvés Assemblée Générale Mixte Mandats Renouvelés ABIONYX Pharma Approbation Unanime Programmes Approuvés
PRESS RELEASE published on 06/27/2024 at 19:22, 4 months 23 days ago Inside Information / Other news releases ABIONYX Pharma announces unanimous approval of all resolutions at its Combined General Meeting. Shareholders renew mandates and approve buyback program Shareholders Buyback Program Renewal Combined General Meeting ABIONYX Pharma
BRIEF published on 06/19/2024 at 21:20, 5 months 1 day ago ABIONYX announces a capital increase without preferential subscription rights Biotechnology Actions United States Increase In Capital Sepsis
BRIEF published on 06/19/2024 at 21:20, 5 months 1 day ago ABIONYX annonce une augmentation de capital sans droit préférentiel de souscription Biotechnologie Actions Augmentation De Capital États-Unis Sepsis
PRESS RELEASE published on 06/19/2024 at 21:15, 5 months 1 day ago Inside Information / Other news releases ABIONYX announces capital increase of c.€3.4 million with share issuance and warrants, strengthening financial position for Sepsis and US development, supported by ORSAY 53 investment company Capital Increase Share Issuance ABIONYX Sepsis Development ORSAY 53
PRESS RELEASE published on 06/19/2024 at 21:15, 5 months 1 day ago Informations privilégiées / Autres communiqués ABIONYX annonce une augmentation de capital de 3,4M€ avec suppression du DPS au profit d'une catégorie de personnes, renforçant sa trésorerie pour le développement dans le sepsis et aux États-Unis Augmentation De Capital États-Unis Sepsis ABIONYX Suppression DPS
BRIEF published on 06/13/2024 at 19:53, 5 months 7 days ago ABIONYX Pharma Receives FDA Approval for New Sepsis Study FDA Clinical Study ABIONYX Pharma Sepsis CER-001
BRIEF published on 06/13/2024 at 19:53, 5 months 7 days ago ABIONYX Pharma obtient l'aval de la FDA pour une nouvelle étude sur le sepsis FDA Étude Clinique ABIONYX Pharma Sepsis CER-001
PRESS RELEASE published on 06/13/2024 at 19:48, 5 months 7 days ago Inside Information / Other news releases ABIONYX Pharma completes successful pre-IND meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial in Sepsis, marking significant progress in developing innovative therapy FDA ABIONYX Pharma Sepsis CER-001 Pre-IND Meeting
Published on 11/21/2024 at 16:01, 26 minutes ago Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 27 minutes ago Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight
Published on 11/21/2024 at 16:00, 27 minutes ago Wiz Acquires Dazz to Revolutionize Cloud Security Remediation
Published on 11/21/2024 at 15:30, 57 minutes ago CLS Health Opens New Comprehensive Care Clinic in Sugar Creek
Published on 11/21/2024 at 15:24, 1 hour 3 minutes ago Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/21/2024 at 15:23, 1 hour 4 minutes ago Form 8.3 - The Vanguard Group, Inc.: Centamin plc
Published on 11/21/2024 at 15:22, 1 hour 5 minutes ago Form 8.3 - The Vanguard Group, Inc.: TI Fluid Systems plc
Published on 11/21/2024 at 06:58, 9 hours 29 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 29 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 29 minutes ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 20 hours 20 minutes ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 21 hours 7 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting